Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Current Deferred Revenue: 2012-2022

Historic Current Deferred Revenue for Agios Pharmaceuticals (AGIO) over the last 7 years, with Mar 2022 value amounting to $2.5 million.

  • Agios Pharmaceuticals' Current Deferred Revenue was N/A to $2.5 million in Q1 2022 from the same period last year, while for Mar 2022 it was $2.5 million, marking a year-over-year change of. This contributed to the annual value of $61.5 million for FY2019, which is 33.51% down from last year.
  • Per Agios Pharmaceuticals' latest filing, its Current Deferred Revenue stood at $2.5 million for Q1 2022, which was down 47.35% from $4.7 million recorded in Q1 2020.
  • In the past 5 years, Agios Pharmaceuticals' Current Deferred Revenue registered a high of $92.5 million during Q4 2018, and its lowest value of $2.5 million during Q1 2022.
  • Moreover, its 2-year median value for Current Deferred Revenue was $3.6 million (2020), whereas its average is $3.6 million.
  • Its Current Deferred Revenue has fluctuated over the past 5 years, first surged by 144.49% in 2018, then slumped by 78.58% in 2020.
  • Quarterly analysis of 4 years shows Agios Pharmaceuticals' Current Deferred Revenue stood at $92.5 million in 2018, then slumped by 33.51% to $61.5 million in 2019, then crashed by 78.58% to $4.7 million in 2020, then reached $2.5 million in 2022.
  • Its last three reported values are $2.5 million in Q1 2022, $4.7 million for Q1 2020, and $61.5 million during Q4 2019.